Abstract
Head and neck squamous cell carcinoma (HNSCC) patients with locoregionally advanced disease usually require multi-modality treatment including surgery, chemotherapy, and radiotherapy. Currently, cisplatin-based concurrent chemoradiation (CRT) remains the gold-standard for these patients [1]. Induction chemotherapy (ICT) prior to definitive therapy is regarded as an effective approach to shrink locally advanced disease allowing more effective and less toxic therapy, to select patients for organ preservation, to improve radiotherapy effectiveness, and also to potentially decrease the risk of distant metastasis due to initial systemic exposure [2].
This article is protected by copyright. All rights reserved.
http://ift.tt/2pKPTnQ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου